148 related articles for article (PubMed ID: 38613352)
1. Integrated analyses for identification of a three-gene signature associated with Chaihu Shugan San formula for hepatocellular carcinoma treatment.
Xing JH; Tan RX; Huang FE; Tian N
J Cell Mol Med; 2024 Apr; 28(8):e18211. PubMed ID: 38613352
[TBL] [Abstract][Full Text] [Related]
2. Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response.
Jiang H; Ning G; Wang Y; Lv W
Dis Markers; 2021; 2021():5576683. PubMed ID: 34221187
[TBL] [Abstract][Full Text] [Related]
3. The role of the key autophagy kinase ULK1 in hepatocellular carcinoma and its validation as a treatment target.
Xue ST; Li K; Gao Y; Zhao LY; Gao Y; Yi H; Jiang JD; Li ZR
Autophagy; 2020 Oct; 16(10):1823-1837. PubMed ID: 31986961
[TBL] [Abstract][Full Text] [Related]
4. Network Pharmacology and Experimental Evidence: PI3K/AKT Signaling Pathway is Involved in the Antidepressive Roles of Chaihu Shugan San.
Zhang S; Lu Y; Chen W; Shi W; Zhao Q; Zhao J; Li L
Drug Des Devel Ther; 2021; 15():3425-3441. PubMed ID: 34385814
[TBL] [Abstract][Full Text] [Related]
5. A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma.
Liu R; Liu Y; Zhang F; Wei J; Wu L
Front Immunol; 2023; 14():1146411. PubMed ID: 37063920
[TBL] [Abstract][Full Text] [Related]
6. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
7. Immunogenic landscape and risk score prediction based on unfolded protein response (UPR)-related molecular subtypes in hepatocellular carcinoma.
Guo H; Zhang S; Zhang B; Shang Y; Liu X; Wang M; Wang H; Fan Y; Tan K
Front Immunol; 2023; 14():1202324. PubMed ID: 37457742
[TBL] [Abstract][Full Text] [Related]
8. Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma.
Zhu J; Huang Q; Peng X; Luo C; Liu Z; Liu D; Yuan H; Yuan R; Cheng X
Front Immunol; 2023; 14():1218661. PubMed ID: 37662906
[TBL] [Abstract][Full Text] [Related]
9. FANCD2 as a novel prognostic biomarker correlated with immune and drug therapy in Hepatitis B-related hepatocellular carcinoma.
Tang X; Luo B; Huang S; Jiang J; Chen Y; Ren W; Shi X; Zhang W; Shi L; Zhong X; Lü M
Eur J Med Res; 2023 Oct; 28(1):419. PubMed ID: 37821996
[TBL] [Abstract][Full Text] [Related]
10. Characterizing the key genes of COVID-19 that regulate tumor immune microenvironment and prognosis in hepatocellular carcinoma.
Gao S; Zhang L; Wang H
Funct Integr Genomics; 2023 Aug; 23(3):262. PubMed ID: 37540264
[TBL] [Abstract][Full Text] [Related]
11. M2-like tumor-associated macrophage-related biomarkers to construct a novel prognostic signature, reveal the immune landscape, and screen drugs in hepatocellular carcinoma.
Qu X; Zhao X; Lin K; Wang N; Li X; Li S; Zhang L; Shi Y
Front Immunol; 2022; 13():994019. PubMed ID: 36177006
[TBL] [Abstract][Full Text] [Related]
12. Identification of the Mechanism of Matrine Combined with Glycyrrhizin for Hepatocellular Carcinoma Treatment through Network Pharmacology and Bioinformatics Analysis.
Han T; Liu Y; Chen Y; Chen T; Li Y; Li Q; Zhao M
Oxid Med Cell Longev; 2022; 2022():2663758. PubMed ID: 36193082
[TBL] [Abstract][Full Text] [Related]
13. A combined molecular biology and network pharmacology approach to investigate the multi-target mechanisms of Chaihu Shugan San on Alzheimer's disease.
Zeng Q; Li L; Siu W; Jin Y; Cao M; Li W; Chen J; Cong W; Ma M; Chen K; Wu Z
Biomed Pharmacother; 2019 Dec; 120():109370. PubMed ID: 31563815
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive network analysis of the molecular mechanisms associated with sorafenib resistance in hepatocellular carcinoma.
Lin H; Zhang R; Wu W; Lei L
Cancer Genet; 2020 Jul; 245():27-34. PubMed ID: 32559715
[TBL] [Abstract][Full Text] [Related]
15. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.
Feng NN; Du XY; Zhang YS; Jiao ZK; Wu XH; Yang BM
Front Endocrinol (Lausanne); 2022; 13():1061091. PubMed ID: 36714595
[TBL] [Abstract][Full Text] [Related]
16. Hexokinase-II Inhibition Synergistically Augments the Anti-tumor Efficacy of Sorafenib in Hepatocellular Carcinoma.
Yoo JJ; Yu SJ; Na J; Kim K; Cho YY; Lee YB; Cho EJ; Lee JH; Kim YJ; Youn H; Yoon JH
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30875800
[TBL] [Abstract][Full Text] [Related]
17. Construction and validation of an angiogenesis-related scoring model to predict prognosis, tumor immune microenvironment and therapeutic response in hepatocellular carcinoma.
Tang B; Zhang X; Yang X; Wang W; Li R; Liu Y
Front Immunol; 2022; 13():1013248. PubMed ID: 36466855
[TBL] [Abstract][Full Text] [Related]
18. Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma.
Liao YJ; Hsu SM; Chien CY; Wang YH; Hsu MH; Suk FM
Molecules; 2020 Jun; 25(12):. PubMed ID: 32575795
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive bioinformatics analysis of a RBM family-based prognostic signature with experiment validation in hepatocellular carcinoma.
Wu Z; Guo L; Wan L; Xu K; Luo L; Wen Z
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11891-11905. PubMed ID: 37410140
[TBL] [Abstract][Full Text] [Related]
20. Cuproptosis regulatory genes greatly contribute to clinical assessments of hepatocellular carcinoma.
Ke C; Dai S; Xu F; Yuan J; Fan S; Chen Y; Yang L; Li Y
BMC Cancer; 2023 Jan; 23(1):25. PubMed ID: 36611155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
